<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="other" dtd-version="1.1" specific-use="sps-1.9" xml:lang="pt">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">xVF5J9ybVW4jJpSjPSbDQFS</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2020000400726</article-id>
      <article-id pub-id-type="publisher-id">abc.20190768</article-id>
      <article-id pub-id-type="doi">10.36660/abc.20190768</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Ponto de Vista</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Tend&#234;ncias de Busca na Internet e Tend&#234;ncias de Mortalidade Regional: O Caso de Anticoagulantes Orais e Acidente Vascular Cerebral</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-0113-9234</contrib-id>
          <name>
            <surname>Ferreira</surname>
            <given-names>Roberto Muniz</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinheiro</surname>
            <given-names>&#205;sis da Capela</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rocha</surname>
            <given-names>Jo&#227;o Roquette Fleury da</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <institution content-type="orgname">Universidade Federal do Rio de Janeiro</institution>
        <institution content-type="orgdiv1">Instituto do Cora&#231;&#227;o &#201;dson Saad</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Universidade Federal do Rio de Janeiro &#8211; Instituto do Cora&#231;&#227;o &#201;dson Saad,Rio de Janeiro, RJ &#8211; Brasil</institution>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <institution content-type="orgname">Hospital Samaritano Botafogo</institution>
        <addr-line>
          <named-content content-type="city">Rio de Janeiro</named-content>
          <named-content content-type="state">RJ</named-content>
        </addr-line>
        <country country="BR">Brasil</country>
        <institution content-type="original">Hospital Samaritano Botafogo &#8211; Cardiologia,Rio de Janeiro, RJ &#8211; Brasil</institution>
      </aff>
      <author-notes>
        <corresp id="c01"> Correspond&#234;ncia: Roberto Muniz Ferreira &#8226; Universidade Federal do Rio de Janeiro - Instituto do Cora&#231;&#227;o &#201;dson Saad - Rua Rodolpho Paulo Rocco, 255. CEP 21941-913, Rio de Janeiro, RJ &#8211; Brasil E-mail: <email>betomf@terra.com.br</email>
				</corresp>
        <fn fn-type="con">
          <p>Contribui&#231;&#227;o dos autores</p>
          <p>Concep&#231;&#227;o e desenho da pesquisa, an&#225;lise e interpreta&#231;&#227;o dos dados, reda&#231;&#227;o do manuscrito e revis&#227;o cr&#237;tica do manuscrito quanto ao conte&#250;do intelectual importante: Ferreira RM, Pinheiro IC, Rocha JRF; Obten&#231;&#227;o de dados e an&#225;lise estat&#237;stica: Ferreira RM.</p>
        </fn>
        <fn fn-type="conflict">
          <p>Potencial conflito de interesses</p>
          <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
        </fn>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
        <day>29</day>
        <month>05</month>
        <year>2020</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2020</year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
        <month>04</month>
        <year>2020</year>
      </pub-date>
      <volume>114</volume>
      <issue>4</issue>
      <fpage>726</fpage>
      <lpage>729</lpage>
      <history>
        <date date-type="received">
          <day>02</day>
          <month>11</month>
          <year>2019</year>
        </date>
        <date date-type="rev-recd">
          <day>02</day>
          <month>12</month>
          <year>2019</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>12</month>
          <year>2019</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
          <license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
        </license>
      </permissions>
      <kwd-group xml:lang="pt">
        <kwd>Acidente Vascular Cerebral/preven&#231;&#227;o e controle</kwd>
        <kwd>Isquemia Mioc&#225;rdica/preven&#231;&#227;o e controle</kwd>
        <kwd>Disponibilidade de Medicamentos via Internet/tend&#234;ncias</kwd>
        <kwd>Anticoagulantes/uso terap&#234;utico</kwd>
        <kwd>Varfarina</kwd>
        <kwd>Dabigatrana</kwd>
        <kwd>Rivaroxabana</kwd>
        <kwd>Mortalidade/tend&#234;ncias</kwd>
      </kwd-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="0"/>
        <equation-count count="0"/>
        <ref-count count="15"/>
        <page-count count="4"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introdu&#231;&#227;o</title>
      <p>V&#225;rios estudos relataram que at&#233; 30% dos casos de acidente vascular cerebral (AVC) isqu&#234;mico est&#227;o associados com fibrila&#231;&#227;o atrial (FA), especialmente na popula&#231;&#227;o idosa.<sup><xref ref-type="bibr" rid="B1">1</xref> , <xref ref-type="bibr" rid="B2">2</xref></sup> Apesar de o risco de embolia variar conforme caracter&#237;sticas cl&#237;nicas e comorbidades, a terapia anticoagulante tem mostrado consistentemente uma redu&#231;&#227;o nas taxas de AVC de aproximadamente 70%.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> No entanto, estudos pr&#233;vios mostraram que as taxas de tratamento com varfarina eram baixas, mesmo em pacientes com risco elevado para eventos. Apesar da evid&#234;ncia de v&#225;rias publica&#231;&#245;es mostrando a efic&#225;cia e a seguran&#231;a dos antagonistas da vitamina K, sua complexa farmacocin&#233;tica e a necessidade de monitoramento cont&#237;nuo e ajustes frequentes da dosagem foram as principais justificativas para baixa ades&#227;o.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
      <p>Durante os &#250;ltimos 10 anos, quatro Anticoagulantes Orais Diretos (AODs) tornaram-se dispon&#237;veis para prevenir eventos emb&#243;licos em pacientes com FA n&#227;o valvular: dabigatrana, rivaroxabana, apixabana e edoxabana. Em agosto de 2011, a dabigatrana foi o primeiro AOD aprovado no Brasil para preven&#231;&#227;o de AVC, seguido da rivaroxabana quatro meses depois. Dois anos depois, a apixabana tamb&#233;m foi introduzida no mercado brasileiro e somente em fevereiro de 2018 a edoxabana se tornou dispon&#237;vel. Compara &#224; varfarina, muitos ensaios sugeriram que os AODs n&#227;o s&#227;o inferiores na preven&#231;&#227;o de AVCs isqu&#234;micos e possivelmente superiores na redu&#231;&#227;o da mortalidade, talvez devido &#224; menor ocorr&#234;ncia de hemorragias intracranianas.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> Al&#233;m de n&#227;o necessitar monitoramento laboratorial, os AODs t&#234;m uma farmacocin&#233;tica mais previs&#237;vel e uma incid&#234;ncia mais baixa de intera&#231;&#245;es medicamentosas. Estudos recentes demonstraram um aumento na taxa de prescri&#231;&#245;es de anticoagulantes entre os m&#233;dicos desde que os AODs se tornaram dispon&#237;veis na pr&#225;tica cl&#237;nica.<sup><xref ref-type="bibr" rid="B1">1</xref></sup></p>
      <p>An&#225;lise de tend&#234;ncia de busca na Internet &#233; um m&#233;todo promissor para estimar a frequ&#234;ncia com que interven&#231;&#245;es m&#233;dicas t&#234;m sido aplicadas na pr&#225;tica cl&#237;nica. Publica&#231;&#245;es mais recentes sugeriram uma forte correla&#231;&#227;o entre os termos inseridos nas buscas na rede, decis&#245;es m&#233;dicas e padr&#245;es de prescri&#231;&#227;o farmacol&#243;gica para uma dada regi&#227;o.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> No entanto, n&#227;o est&#225; claro se esses padr&#245;es de busca tamb&#233;m s&#227;o preditivos de tend&#234;ncias regionais associadas a ventos cl&#237;nicos.</p>
    </sec>
    <sec>
      <title>Tend&#234;ncias de busca na Internet na assist&#234;ncia &#224; sa&#250;de</title>
      <p>Atualmente, o Google talvez seja a ferramenta de busca mais utilizada, mesmo entre os profissionais de sa&#250;de. Os padr&#245;es de busca criados dentro do Google est&#227;o dispon&#237;veis desde 2004 e podem ser acessados a partir do Google Trends (Google Inc. Mountain View, CA, EUA). Em resumo, trata-se de uma ferramenta de acesso aberto que apresenta com que frequ&#234;ncia um dado termo ou t&#243;pico foi buscado no programa de busca Google. Al&#233;m disso, podem ser aplicados filtros para especificar uma regi&#227;o e o per&#237;odo para a an&#225;lise. A frequ&#234;ncia &#225; apresentada como um n&#250;mero entre 0 e 100, que varia ao longo do intervalo de tempo pr&#233;-definido e representa uma propor&#231;&#227;o em rela&#231;&#227;o ao ponto mais alto de popularidade. Assim, um valor de 100 indica o momento em que o termo ou t&#243;pico alcan&#231;ou o interesse mais alto de busca, e um valor de zero correlaciona-se com menos que 1% da popularidade m&#225;xima.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Al&#233;m disso, at&#233; cinco termos podem ser analisados simultaneamente, e um valor m&#233;dio de popularidade &#233; automaticamente gerado para cada termo durante o intervalo selecionado.</p>
      <p>Os sistemas de busca de Internet t&#234;m o potencial de refletir o interesse geral de uma popula&#231;&#227;o sobre um dado t&#243;pico, dentro de um intervalo de tempo e uma regi&#227;o espec&#237;ficos. O Google Trends &#233; um exemplo dessa ferramenta, e seus escores resultam de muitos fatores que influenciam diretamente o entendimento do p&#250;blico acerca do assunto pesquisado. Esses fatores incluem campanhas promocionais, cobertura da m&#237;dia, taxas de alfabetiza&#231;&#227;o e status socioecon&#244;mico. No entanto, quando pacientes e profissionais de sa&#250;de s&#227;o expostos &#224; informa&#231;&#227;o e conhecimento, existe uma maior probabilidade de uma tomada de decis&#227;o informada em rela&#231;&#227;o &#224; implementa&#231;&#227;o de interven&#231;&#245;es m&#233;dicas.</p>
      <p>Um estudo de Kritz et al.,<sup><xref ref-type="bibr" rid="B7">7</xref></sup> mostrou que os m&#233;dicos utilizam frequentemente sistemas gerais de busca para obterem conhecimento m&#233;dico na pr&#225;tica di&#225;ria, principalmente pela falta de tempo para uma pesquisa mais ampla.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Al&#233;m disso, alguns pa&#237;ses utilizam sistemas de busca como ferramentas de pesquisa epidemiol&#243;gica para uma variedade de doen&#231;as, o que poderia ter implica&#231;&#245;es nas pol&#237;ticas p&#250;blicas de sa&#250;de. Na Fran&#231;a, o Sentinel Network &#233; um sistema p&#250;blico de monitoramento de sa&#250;de p&#250;blica em que m&#233;dicos cl&#237;nicos gerais utilizam dados baseados em rede para acompanharem padr&#245;es de doen&#231;as e potencialmente identificarem surtos em est&#225;gio inicial.<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
      <p>Apesar de escores de popularidade n&#227;o necessariamente refletirem os padr&#245;es de prescri&#231;&#227;o de medicamentos, estudos anteriores incluindo uma ampla variedade de medicamentos sugeriram que uma associa&#231;&#227;o de fato existe. Essa associa&#231;&#227;o foi demonstrada com estatinas e v&#225;rios medicamentos n&#227;o cardiovasculares.<sup><xref ref-type="bibr" rid="B9">9</xref> , <xref ref-type="bibr" rid="B10">10</xref></sup> Um estudo de Lippi et al.,<sup><xref ref-type="bibr" rid="B6">6</xref></sup> tamb&#233;m apontou um aumento no volume de busca online por AODs, o que condiz com o r&#225;pido aumento na pr&#225;tica cl&#237;nica.</p>
    </sec>
    <sec>
      <title>Tend&#234;ncias de busca na Internet para anticoagulantes orais e AVC</title>
      <p>Apesar do aumento progressivo no n&#250;mero de publica&#231;&#245;es nessa &#225;rea, a associa&#231;&#227;o entre padr&#245;es espec&#237;ficos de busca de tratamento e varia&#231;&#245;es subsequentes nos eventos cl&#237;nicos populacionais necessita ainda ser demonstrada. Se uma rela&#231;&#227;o realmente existe, os dados de busca poderiam funcionar como um substituto para efeitos em grande escala de um dado tratamento farmacol&#243;gico ou interven&#231;&#227;o em rela&#231;&#227;o a desfechos cl&#237;nicos espec&#237;ficos. A influ&#234;ncia de anticoagulantes orais na epidemiologia de mortes relacionadas a AVC serve como um exemplo adequado nesse cen&#225;rio, considerando que a maioria dos eventos cerebrovasculares isqu&#234;micos s&#227;o cardioemb&#243;licos e prevenidos por anticoagulantes orais. Hernandez et al.,<sup><xref ref-type="bibr" rid="B11">11</xref></sup> correlacionaram a varia&#231;&#227;o geogr&#225;fica no uso de anticoagulantes e as taxas de AVC em usu&#225;rios do Medicare, demonstrando uma rela&#231;&#227;o inversa entre as duas vari&#225;veis.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
      <p>Segundo o departamento de tecnologia da informa&#231;&#227;o do Sistema &#218;nico de Sa&#250;de (DATASUS), o n&#250;mero total de mortes relacionadas a AVC no Brasil diminuiu de 2006 a 2015, apesar que a redu&#231;&#227;o mais significativa tenha ocorrido ap&#243;s 2011.<sup><xref ref-type="bibr" rid="B12">12</xref></sup> Al&#233;m disso, AVC isqu&#234;mico e os casos de AVC sem classifica&#231;&#227;o espec&#237;fica (ICD-10 c&#243;digos I63 e I64) foram a maioria dos eventos cerebrovasculares (70.2%), e apresentaram um padr&#227;o similar de decl&#237;nio ap&#243;s 2011 (m&#233;dia de 49 406,4 &#177; 451 vs. 46447,2 &#177; 1633 de &#243;bitos por ano antes e ap&#243;s 2011, respectivamente). Por outro lado, mortes por AVC hemorr&#225;gico (ICD-10 c&#243;digos I60, I61 e I62) aumentaram no mesmo per&#237;odo, apesar que em uma propor&#231;&#227;o bem menor (m&#233;dia de 19 740,4 &#177; 278 vs. 20 933.8 &#177; 446 de &#243;bitos por ano antes e ap&#243;s 2011, respectivamente).<sup><xref ref-type="bibr" rid="B13">13</xref></sup></p>
      <p>Durante o mesmo per&#237;odo, quando varfarina, dabigatrana e rivaroxabana foram usadas como t&#243;picos de busca, e o Brasil como a &#250;nica regi&#227;o de busca, observou-se um franco decl&#237;nio nos escores do Google Trands para varfarina ap&#243;s 2011. Em 2015, o valor de popularidade havia atingido aproximadamente o mesmo n&#237;vel que em 2009. Por outro lado, o score para rivaroxabana aumentou consideravelmente ap&#243;s 2011, e ultrapassou a popularidade da varfarina ap&#243;s 2013. O escore de busca para dabigarana permaneceu consistentemente abaixo dos outros dois anticoagulantes por todo o per&#237;odo de tempo analisado. Deve-se ressaltar que, quando um t&#243;pico (ou seja, &#8220;medicamento&#8221;) &#233; usado como op&#231;&#227;o de busca, os termos associados ao medicamento, incluindo nomes comerciais, tamb&#233;m s&#227;o contemplados.</p>
      <p>Quando as mortes relacionadas a AVC e escores de busca s&#227;o analisados em combina&#231;&#227;o, parece existir uma correla&#231;&#227;o inversa com AVC isqu&#234;mico e uma associa&#231;&#227;o positiva com eventos hemorr&#225;gicos. Entre 2011 e 2015, mortalidade total e por AVC isqu&#234;mico diminuiu ( <xref ref-type="fig" rid="f01">Figura 1</xref> ), ao passo que eventos hemorr&#225;gicos aumentaram ( <xref ref-type="fig" rid="f02">Figura 2</xref> ) concomitantemente ao aumento dos escores do Google Trends para AODs. Mais importante, essa rela&#231;&#227;o parece ter sido primariamente causada por um aumento da popularidade da rivaroxabana.</p>
      <p>
        <fig id="f01">
          <label>Figura 1</label>
          <caption>
            <title>&#8211; <italic>Mortes por acidente vascular cerebral isqu&#234;mico por ano e m&#233;dia de escores do Google Trends para anticoagulantes. Ap&#243;s 2011, houve um aumento na popularidade online da rivaroxabana acompanhada por um decr&#233;scimo no n&#250;mero total de mortes relacionadas a acidente vascular cerebral isqu&#234;mico no Brasil.</italic></title>
          </caption>
          <graphic xlink:href="1678-4170-abc-114-04-0726-90768-gf01.jpg"/></fig>
      </p>
      <p>
        <fig id="f02">
          <label>Figura 2</label>
          <caption>
            <title>&#8211; <italic>Mortes por acidente vascular cerebral hemorr&#225;gico por ano e m&#233;dia de escores do Google Trends para anticoagulantes. Ap&#243;s 2011, houve um aumento na popularidade online da rivaroxabana acompanhada por um aumento escalonado no n&#250;mero de mortes relacionadas a acidente vascular cerebral hemorr&#225;gico no Brasil.</italic></title>
          </caption>
          <graphic xlink:href="1678-4170-abc-114-04-0726-90768-gf02.jpg"/></fig>
      </p>
      <p>Uma vez que tem ocorrido um aumento progressivo na prescri&#231;&#227;o de anticoagulantes orais na pr&#225;tica cl&#237;nica, al&#233;m de um aumento na popularidade dos AODs na Internet em todo o mundo, modifica&#231;&#245;es na incid&#234;ncia de eventos cerebrovasculares isqu&#234;micos e hemorr&#225;gicos podem ser antecipadas.<sup><xref ref-type="bibr" rid="B1">1</xref> , <xref ref-type="bibr" rid="B6">6</xref></sup> No Brasil, tal impacto tamb&#233;m seria esperado, j&#225; que desde 2015 a rivaroxabana j&#225; era a droga de maior receita de venda no mercado nacional, apenas quatro anos ap&#243;s ter se tornado dispon&#237;vel ao p&#250;blico.<sup><xref ref-type="bibr" rid="B14">14</xref></sup> Em apenas dois anos, a rivaroxabana ultrapassou a varfarina em volume de busca na Internet na maior parte do pa&#237;s. Esses achados provavelmente se devem a um aumento no uso de AODs, em vez de uma transi&#231;&#227;o entre categorias de anticoagulantes. Os AODs tornaram-se op&#231;&#245;es atrativas quando a preven&#231;&#227;o de AVC &#233; considerada em FA, principalmente devido &#224; sua farmacocin&#233;tica previs&#237;vel, provavelmente maior seguran&#231;a e efic&#225;cia n&#227;o inferior &#224; de antagonistas da vitamina K.</p>
      <p>Ao contr&#225;rio do que foi encontrado em rela&#231;&#227;o a AVC isqu&#234;mico, mortes relacionadas a AVC hemorr&#225;gico aparentemente aumentaram desde 2011. Apesar de tal aumento haver ocorrido em uma taxa mais lenta, a tend&#234;ncia parece tamb&#233;m estar relacionada aos padr&#245;es de busca por rivaroxabana. Talvez essa tend&#234;ncia tenha sido consequente ao grande n&#250;mero de pacientes sem tratamento pr&#233;vio que progressivamente receberam anticoagulantes, j&#225; que os AODs tendem a reduzir sangramento intracraniano em compara&#231;&#227;o &#224; varfarina.</p>
      <p>A maior utiliza&#231;&#227;o do escore CHA<sub>2</sub>DS<sub>2</sub>-Vasc Score tamb&#233;m pode ter contribu&#237;do para o aumento no n&#250;mero de pacientes recebendo terapia anticoagulante durante o per&#237;odo de estudo.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Al&#233;m disso, considerando que a mortalidade total por AVC diminuiu significativamente, o padr&#227;o epidemiol&#243;gico &#233; compar&#225;vel ao benef&#237;cio l&#237;quido dos AODs descrito em muitos ensaios.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> A possibilidade de que outros fatores, tais como pol&#237;ticas de sa&#250;de p&#250;blica, maior controle dos fatores de risco cardiovascular, e melhores condi&#231;&#245;es socioecon&#244;micas, possa ter influenciado o n&#250;mero anual de mortes n&#227;o pode ser exclu&#237;da. Contudo, uma redu&#231;&#227;o nas mortes relacionadas a AVC hemorr&#225;gico tamb&#233;m j&#225; seria esperada como resultado dessas interven&#231;&#245;es. At&#233; 2017, observou-se um decl&#237;nio consistente nas mortes isqu&#234;micas, enquanto os eventos hemorr&#225;gicos continuaram a aumentar.<sup><xref ref-type="bibr" rid="B12">12</xref></sup></p>
      <p>Apesar de os escores de busca fornecerem uma estimativa dos padr&#245;es de prescri&#231;&#227;o, n&#227;o s&#227;o um reflexo direto de utiliza&#231;&#227;o ou vendas regionais dos medicamentos. O acesso &#224; Internet em 2014 estava dispon&#237;vel em aproximadamente 50% dos domic&#237;lios no Brasil e a taxa de analfabetismo em indiv&#237;duos acima de 65 anos ainda era alta (26,4%).<sup><xref ref-type="bibr" rid="B15">15</xref></sup> Assim, esses padr&#245;es devem ser interpretados considerando todos os potenciais vieses, principalmente pelo fato de os algoritmos espec&#237;ficos empregados pelo Google Trends n&#227;o terem sido apresentados. Por&#233;m, uma vez que o acesso &#224; Internet aumenta em todo o mundo, e novas pol&#237;ticas s&#227;o desenvolvidas para a redu&#231;&#227;o das taxas de analfabetismo, as tend&#234;ncias de busca se tornar&#227;o cada vez mais correlacionados a padr&#245;es di&#225;rios de comportamento.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclus&#227;o</title>
      <p>O progressivo crescimento da popula&#231;&#227;o mundial tem demandado o desenvolvimento de novos mecanismos para monitorar mudan&#231;as epidemiol&#243;gicas tanto nas tend&#234;ncias de tratamento como nos padr&#245;es de doen&#231;a. Nesse contexto, a Internet tornou-se uma ferramenta valiosa para reunir informa&#231;&#245;es na tomada de decis&#227;o di&#225;ria, particularmente no cuidado &#224; sa&#250;de, em que a an&#225;lise cr&#237;tica dos dados coletados tamb&#233;m &#233; de suma import&#226;ncia. Nos &#250;ltimos dez anos, o aumento em experi&#234;ncia cl&#237;nica com AODs em pacientes com FA foi acompanhado por um aumento global significativo na popularidade dessas drogas em sistemas de busca na Internet. Esse fen&#244;meno parece tamb&#233;m estar ocorrendo em pa&#237;ses de renda m&#233;dia, tal como o Brasil. No entanto, a associa&#231;&#227;o entre tend&#234;ncias de buscas na rede e desfechos cl&#237;nicos continua uma &#225;rea pouco estudada. Existe a possibilidade de que a efic&#225;cia de pol&#237;ticas de sa&#250;de e interven&#231;&#245;es em grande escala, tais como campanhas de vacina&#231;&#227;o, possam ser monitoradas por dados de busca online, principalmente em regi&#245;es onde a maioria da popula&#231;&#227;o tem acesso &#224; Internet. &#193;reas espec&#237;ficas da medicina onde essa estrat&#233;gia possa ser valiosa precisam ser determinadas e exploradas em estudos futuros.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Agradecimentos</title>
      <p>Este estudo recebeu o apoio da Universidade Federal do Rio de Janeiro e do Instituto do Cora&#231;&#227;o Edson Saad.</p>
    </ack>
    <ref-list>
      <title>Refer&#234;ncias</title>
      <ref id="B1">
        <label>1</label>
        <mixed-citation>1. Katz D, Maddox T, Turakhia M, Gehi A, O&#8217;Brien E, Lubitz S, et al. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS 2 to the CHA 2 DS 2 -VASc Score for Thromboembolic Risk Assessment. Circ Cardiovasc Qual Outcomes. 2017;10(5):e003476.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katz</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Maddox</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Turakhia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gehi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>O&#8217;Brien</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lubitz</surname>
              <given-names>S</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS 2 to the CHA 2 DS 2 -VASc Score for Thromboembolic Risk Assessment</article-title>
          <source>Circ Cardiovasc Qual Outcomes</source>
          <year>2017</year>
          <volume>10</volume>
          <issue>5</issue>
          <elocation-id>e003476</elocation-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <mixed-citation>2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kirchhof</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Benussi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kotecha</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ahlsson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Atar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Casadei</surname>
              <given-names>B</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS</article-title>
          <source>Eur Heart J</source>
          <year>2016</year>
          <volume>37</volume>
          <issue>38</issue>
          <fpage>2893</fpage>
          <lpage>2962</lpage>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <mixed-citation>3. Buckingham T, Hatala R. Anticoagulants for atrial fibrillation: Why is the treatment rate so low?. Clin Cardiol. 2002;25(10):447-54.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Buckingham</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hatala</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Anticoagulants for atrial fibrillation: Why is the treatment rate so low?</article-title>
          <source>Clin Cardiol</source>
          <year>2002</year>
          <volume>25</volume>
          <issue>10</issue>
          <fpage>447</fpage>
          <lpage>454</lpage>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <mixed-citation>4. L&#243;pez-L&#243;pez J, Sterne J, Thom H, Higgins J, Hingorani A, Okoli J, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5631.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>L&#243;pez-L&#243;pez</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sterne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thom</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Higgins</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hingorani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Okoli</surname>
              <given-names>J</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis</article-title>
          <source>BMJ</source>
          <year>2017</year>
          <volume>359</volume>
          <size units="pages">j5631</size>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <mixed-citation>5. Moat H, Olivola C, Chater N, Preis T. Searching Choices: Quantifying Decision-Making Processes Using Search Engine Data. Top Cogn Sci. 2016;8(3):685-96.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moat</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Olivola</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chater</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Preis</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Searching Choices: Quantifying Decision-Making Processes Using Search Engine Data</article-title>
          <source>Top Cogn Sci</source>
          <year>2016</year>
          <volume>8</volume>
          <issue>3</issue>
          <fpage>685</fpage>
          <lpage>696</lpage>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <mixed-citation>6. Lippi G, Mattiuzzi C, Cervellin G, Favaloro E. Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends. Ann Transl Med. 2017;5(16):322.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lippi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mattiuzzi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cervellin</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Favaloro</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends</article-title>
          <source>Ann Transl Med</source>
          <year>2017</year>
          <volume>5</volume>
          <issue>16</issue>
          <size units="pages">322</size>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <mixed-citation>7. Kritz M, Gschwandtner M, Stefanov V, Hanbury A, Samwald M. Utilization and Perceived Problems of Online Medical Resources and Search Tools Among Different Groups of European Physicians. J Med Internet Res. 2013;15(6):e122.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kritz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gschwandtner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stefanov</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hanbury</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Samwald</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Utilization and Perceived Problems of Online Medical Resources and Search Tools Among Different Groups of European Physicians</article-title>
          <source>J Med Internet Res</source>
          <year>2013</year>
          <volume>15</volume>
          <issue>6</issue>
          <elocation-id>e122</elocation-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <mixed-citation>8. Blanchon T. Web-based sentinel provider surveillance network in France. In: Nkuchia M, Lynfield R, Van Beneden CA, de Valk H, eds. Infectious dsease surveillance. Philadelphia: Willey-Blackwell; 2013. p.418-25.</mixed-citation>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Blanchon</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <chapter-title>Web-based sentinel provider surveillance network in France</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Nkuchia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lynfield</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Van Beneden</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>de Valk</surname>
              <given-names>H</given-names>
            </name>
            <role>eds</role>
          </person-group>
          <source>Infectious dsease surveillance</source>
          <publisher-loc>Philadelphia</publisher-loc>
          <publisher-name>Willey-Blackwell</publisher-name>
          <year>2013</year>
          <fpage>418</fpage>
          <lpage>425</lpage>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <mixed-citation>9. Simmering J, Polgreen L, Polgreen P. Web search query volume as a measure of pharmaceutical utilization and changes in prescribing patterns. Res Social Adm Pharm 2014;10(6):896-903.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmering</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Polgreen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Polgreen</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Web search query volume as a measure of pharmaceutical utilization and changes in prescribing patterns</article-title>
          <source>Res Social Adm Pharm</source>
          <year>2014</year>
          <volume>10</volume>
          <issue>6</issue>
          <fpage>896</fpage>
          <lpage>903</lpage>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <mixed-citation>10. Schuster N, Rogers M, McMahon L. Using Search Engine Query Data to Track Pharmaceutical Utilization: A Study of Statins. Am J Manag Care 2010;16(8): e215&#8211;9.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schuster</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Rogers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Using Search Engine Query Data to Track Pharmaceutical Utilization: A Study of Statins</article-title>
          <source>Am J Manag Care</source>
          <year>2010</year>
          <volume>16</volume>
          <issue>8</issue>
          <fpage>e215</fpage>
          <lpage>e219</lpage>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <mixed-citation>11. Hernandez, I., Saba, S. and Zhang, Y. Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation. Stroke 2017;48(8):2289-91.</mixed-citation>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hernandez</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Saba</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation</article-title>
          <source>Stroke</source>
          <year>2017</year>
          <volume>48</volume>
          <issue>8</issue>
          <fpage>2289</fpage>
          <lpage>2291</lpage>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <mixed-citation>12. Brasil. Minist&#233;rio da Sa&#250;de. Datasus. Informa&#231;&#245;es estat&#237;sticas da sa&#250;de. Brasilia; 2018.</mixed-citation>
        <element-citation publication-type="report">
          <person-group person-group-type="author">
            <collab>Brasil</collab>
            <collab>Minist&#233;rio da Sa&#250;de</collab>
            <collab>Datasus</collab>
          </person-group>
          <source>Informa&#231;&#245;es estat&#237;sticas da sa&#250;de</source>
          <publisher-loc>Brasilia</publisher-loc>
          <year>2018</year>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <mixed-citation>13. World Health Organization . (WHO). International Classification of Diseases. Washington; 2018.</mixed-citation>
        <element-citation publication-type="report">
          <person-group person-group-type="author">
            <collab>World Health Organization . (WHO)</collab>
          </person-group>
          <source>International Classification of Diseases</source>
          <publisher-loc>Washington</publisher-loc>
          <year>2018</year>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <mixed-citation>14. Interfarma. Associa&#231;&#227;o da Ind&#250;stria Farmac&#234;utica de Pesquisa; Guia 2016 Interfarma. S&#227;o Paulo; 2016.</mixed-citation>
        <element-citation publication-type="report">
          <person-group person-group-type="author">
            <collab>Interfarma</collab>
            <collab>Associa&#231;&#227;o da Ind&#250;stria Farmac&#234;utica de Pesquisa</collab>
          </person-group>
          <source>Guia 2016 Interfarma</source>
          <publisher-loc>S&#227;o Paulo</publisher-loc>
          <year>2016</year>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <mixed-citation>15. Instituto Brasileiro de Geografia e Estat&#237;stica. (IBGE). Indicadores 2015. Rio de Janeiro; 2018.</mixed-citation>
        <element-citation publication-type="report">
          <person-group person-group-type="author">
            <collab>Instituto Brasileiro de Geografia e Estat&#237;stica. (IBGE)</collab>
          </person-group>
          <source>Indicadores 2015</source>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <year>2018</year>
        </element-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn fn-type="other">
        <p>Vincula&#231;&#227;o acad&#234;mica</p>
        <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
      </fn>
      <fn fn-type="other">
        <p>Aprova&#231;&#227;o &#233;tica e consentimento informado</p>
        <p>Este artigo n&#227;o cont&#233;m estudos com humanos ou animais realizados por nenhum dos autores.</p>
      </fn>
    </fn-group>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Fontes de financiamento</p>
        <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
      </fn>
    </fn-group>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Viewpoint</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Internet Search Trends and Regional Mortality Tendencies: The Case of Oral Anticoagulants and Stroke</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid">0000-0003-0113-9234</contrib-id>
          <name>
            <surname>Ferreira</surname>
            <given-names>Roberto Muniz</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinheiro</surname>
            <given-names>&#205;sis da Capela</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rocha</surname>
            <given-names>Jo&#227;o Roquette Fleury da</given-names>
          </name>
          <xref ref-type="aff" rid="aff1001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff2001">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1001">
        <label>1</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Universidade Federal do Rio de Janeiro &#8211; Instituto do Cora&#231;&#227;o &#201;dson Saad, Rio de Janeiro, RJ &#8211; Brazil</institution>
      </aff>
      <aff id="aff2001">
        <label>2</label>
        <country country="BR">Brazil</country>
        <institution content-type="original">Hospital Samaritano Botafogo &#8211; Cardiologia, Rio de Janeiro, RJ &#8211; Brazil</institution>
      </aff>
      <author-notes>
        <corresp id="c01001">Mailing Address: Roberto Muniz Ferreira &#8226; Universidade Federal do Rio de Janeiro - Instituto do Cora&#231;&#227;o &#201;dson Saad - Rua Rodolpho Paulo Rocco, 255. Postal Code 21941-913, Rio de Janeiro, RJ &#8211; Brazil E-mail: betomf@terra.com.br</corresp>
        <fn fn-type="con">
          <p>Author contributions</p>
          <p>Conception and design of the research, analysis and interpretation of the data, writing of the manuscript and critical revision of the manuscript for intellectual content: Ferreira RM, Pinheiro IC, Rocha JRF; Acquisition of data and Statistical analysis: Ferreira RM.</p>
        </fn>
        <fn fn-type="conflict">
          <p>Potential Conflict of Interest</p>
          <p>No potential conflict of interest relevant to this article was reported.</p>
        </fn>
      </author-notes>
      <kwd-group xml:lang="en">
        <kwd>Stroke/prevention and control</kwd>
        <kwd>Myocardial Ischemia/prevention and control</kwd>
        <kwd>Pharmaceutical Services, Online/trends</kwd>
        <kwd>Anticoagulants/therapeutic use</kwd>
        <kwd>Varfarin</kwd>
        <kwd>Dabigatran</kwd>
        <kwd>Rivaroxaban</kwd>
        <kwd>Mortality/trends</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec sec-type="intro">
        <title>Introduction</title>
        <p>Multiple studies have found that up to 30% of ischemic strokes are associated with atrial fibrillation (AF), especially in the elderly population.<sup><xref ref-type="bibr" rid="B1">1</xref> , <xref ref-type="bibr" rid="B2">2</xref></sup> Although the embolic risk varies according to clinical characteristics and comorbidities, anticoagulant therapy has consistently shown to reduce stroke rates by approximately 70%.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> However, previous studies demonstrated that treatment rates with warfarin were low, even in patients at high risk for embolic events. Despite evidence from various publications demonstrating the effectiveness and safety of vitamin K antagonists, their complex pharmacokinetics and the need for continuous monitoring and frequent dose adjustments were the main explanations for low adherence.<sup><xref ref-type="bibr" rid="B3">3</xref></sup></p>
        <p>Over the last 10 years, four direct oral anticoagulants (DOAC) have become available to prevent embolic events in patients with non-valvular AF: dabigatran, rivaroxaban, apixaban and edoxaban. In August 2011, dabigatran was the first DOAC approved in Brazil for stroke prevention, followed by rivaroxaban four months later. Two years later, apixaban was also introduced in the Brazilian market and only in February 2018 edoxaban became available. When compared to warfarin, multiple trials have suggested that DOACs are non-inferior in preventing ischemic strokes and possibly superior in reducing mortality, perhaps due to fewer intracranial hemorrhages.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> In addition to waive the need for laboratory monitoring, they have more predictable pharmacokinetics and a lower incidence of drug-to-drug interactions. Recent studies have demonstrated an increase in anticoagulation prescription rates among physicians since DOACs have become clinically available.<sup><xref ref-type="bibr" rid="B1">1</xref></sup></p>
        <p>The analysis of Internet search trends is a promising method for estimating the frequency by which medical interventions are being applied in clinical practice. More recent publications have suggested a strong correlation between Internet search engine query data, medical decision making and pharmacological prescription patterns for a given region.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> However, it is not clear whether these search patterns are also predictive of regional trends associated with clinical events.</p>
      </sec>
      <sec>
        <title>Internet search trends in health care</title>
        <p>Currently, Google is perhaps the most utilized online search tool, even among healthcare professionals. The search patterns created within Google have been available since 2004 and can be accessed from Google Trends (Google Inc. Mountain View, CA, USA). Briefly, this is an open-access tool which displays how frequently any given term or topic has been searched for in the Google search engine. Additionally, filters can be used to specify a region and time period for the analysis. The frequency is presented as a number from 0 to 100 which varies over the predefined time interval and represents a proportion in relation to the highest popularity point. Accordingly, a value of 100 indicates the moment at which the term or topic reached the highest search interest, and a value of zero correlates to less than 1% of the peak popularity.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> Also, up to five terms or topics can be analyzed simultaneously, and a mean popularity value is automatically provided for each term during the selected interval.</p>
        <p>Internet search engines have the potential to reflect the general interest of a population in a given topic, within a specific time interval and region. Google Trends is an example of such a tool, and the scores provided the website are a result of many factors that directly influence the public&#8217;s awareness regarding the subject being researched. These include promotional campaigns, media coverage, internet access, literacy rates and socioeconomic status. Nevertheless, when patients and health care professionals are exposed to information and knowledge, there is a higher probability of an informed decision regarding the implementation of medical interventions.</p>
        <p>A study by Kritz et al.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> demonstrated that physicians frequently use general search engines to retrieve medical knowledge in daily practice, chiefly because of lack of time for a more thorough research.<sup><xref ref-type="bibr" rid="B7">7</xref></sup> Furthermore, some countries use search engines as epidemiological surveillance tools for a variety of diseases, which could have implications in public health policies. In France, the Sentinel Network is a public health monitoring system where general practitioners use web-based data to follow disease patterns and potentially identify outbreaks at an early stage.<sup><xref ref-type="bibr" rid="B8">8</xref></sup></p>
        <p>Although popularity scores do not necessarily mirror drug prescription patterns, previous studies with a wide variety of medications have suggested that an association does in fact exist. This association has been shown with statins and several non-cardiovascular drugs.<sup><xref ref-type="bibr" rid="B9">9</xref> , <xref ref-type="bibr" rid="B10">10</xref></sup> A previous study by Lippi et al.<sup><xref ref-type="bibr" rid="B6">6</xref></sup> also found an increase in worldwide online search volume for DOACs, which has been consistent with the escalation in clinical use.</p>
      </sec>
      <sec>
        <title>Internet search trends for oral anticoagulants and stroke</title>
        <p>Despite a progressive increase in the number of publications in this area, an association between specific patterns of treatment search and subsequent variations in populational clinical events has yet to be clearly demonstrated. If a relationship really exists, search data would have the potential to function as a surrogate for large-scale effects of a given drug or intervention regarding specific clinical outcomes. The influence of oral anticoagulants in the epidemiology of stroke-related deaths serves as an adequate example in this scenario, considering that most ischemic cerebrovascular events are cardioembolic and effectively prevented by oral anticoagulants. Hernandez et al.<sup><xref ref-type="bibr" rid="B11">11</xref></sup> have previously correlated geographic variation in the use of anticoagulation with stroke rates among Medicare beneficiaries, demonstrating an inverse relationship between the two variables.<sup><xref ref-type="bibr" rid="B11">11</xref></sup></p>
        <p>According to the Department of Information Technology of the Brazilian Unified Health System (DATASUS), the total number of stroke-related deaths in Brazil declined between 2006 and 2015, although the most significant reduction was after 2011.<sup><xref ref-type="bibr" rid="B12">12</xref></sup> In addition, ischemic strokes and those not classified as a specific type (ICD-10 codes I63 and I64) comprised most of the cerebrovascular events (70,2%), and presented a similar pattern of decline since 2011 (mean of 49,406.4 &#177; 451 vs. 46,447.2 &#177; 1633 deaths per year before and after 2011, respectively). Conversely, hemorrhagic stroke deaths (ICD-10 codes I60, I61 and I62) increased in the same period, albeit at a much lower proportion (mean of 19,740.4 &#177; 278 vs 20,933.8 &#177; 446 deaths per year before and after 2011, respectively).<sup><xref ref-type="bibr" rid="B13">13</xref></sup></p>
        <p>During the same period, when warfarin, dabigatran and rivaroxaban were used as search topics (&#8220;drug&#8221;) and Brazil was defined as the only search region, there was a clear tendency for a decline in warfarin&#8217;s Google Trends search scores after 2011. In 2015 the popularity value reached approximately the same level as 2009. Conversely, rivaroxaban&#8217;s score increased considerably after 2011, and surpassed warfarin&#8217;s popularity after 2013. Dabigatran&#8217;s search score remained consistently below the other two anticoagulants throughout the analyzed time interval. It should be noted that when a topic (i.e. &#8220;drug&#8221;) is used as the search option, terms that are associated with the corresponding drug, including commercial names, are also contemplated.</p>
        <p>When stroke-related deaths and search scores are appreciated in combination there appears to be an inverse correlation with ischemic strokes and a positive association with hemorrhagic events. Between 2011 and 2015, total and ischemic stroke deaths decreased ( <xref ref-type="fig" rid="f01001">Figure 1</xref> ) and hemorrhagic events increased ( <xref ref-type="fig" rid="f02001">Figure 2</xref> ) concurrently to an escalation in DOAC Google Trends&#8217; search scores. Most importantly, this relationship seemed to be primarily driven by a rise in rivaroxaban&#8217;s popularity.</p>
        <p>
          <fig id="f01001">
            <label>Figure 1</label>
            <caption>
              <title>&#8211; <italic>Annual ischemic stroke-related deaths and mean Google Trends scores for anticoagulants. After 2011, an increase in the online popularity of rivaroxaban was accompanied by a decrease in the number of ischemic stroke related-deaths in Brazil.</italic></title>
            </caption>
            <graphic xlink:href="1678-4170-abc-114-04-0726-90768-gf01-en.jpg"/></fig>
        </p>
        <p>
          <fig id="f02001">
            <label>Figure 2</label>
            <caption>
              <title>&#8211; <italic>Annual hemorrhagic stroke-related deaths and mean anticoagulant Google Trends scores. After 2011, an increase in rivaroxaban&#8217;s online popularity was accompanied by an escalation in the total number of hemorrhagic stroke related-deaths in Brazil.</italic></title>
            </caption>
            <graphic xlink:href="1678-4170-abc-114-04-0726-90768-gf02-en.jpg"/></fig>
        </p>
        <p>Since there has been a progressive increase in the prescription of oral anticoagulants in clinical practice, and also a rise in the internet popularity of DOAC worldwide, changes in the incidence of both ischemic and hemorrhagic cerebrovascular events may be anticipated.<sup><xref ref-type="bibr" rid="B1">1</xref> , <xref ref-type="bibr" rid="B6">6</xref></sup> In Brazil, such an impact would also be expected, since in 2015 rivaroxaban was already the drug with the third highest sales revenue in the national market, only four years after it became available to the public.<sup><xref ref-type="bibr" rid="B14">14</xref></sup> In only two years, rivaroxaban surpassed warfarin in Internet search volume in most of the country. This finding is probably related to an increase in the use of DOACs, rather than a transition between anticoagulant categories. DOACs have become attractive options when stroke prevention is considered in AF, mainly because of their predictable pharmacokinetics, probably safer profile and non-inferior effectiveness when compared to vitamin K antagonists.</p>
        <p>Contrary to what was found with ischemic strokes, hemorrhagic stroke-related deaths apparently increased since 2011. Although such an escalation occurred at a lower rate, the trend also appeared to be related to rivaroxaban&#180;s search patterns. Perhaps this tendency was also a result of a greater number of previously untreated patients that progressively received anticoagulants, since DOACs tend to reduce intracranial bleeding when compared to warfarin.</p>
        <p>The greater adoption of the CHA<sub>2</sub>DS<sub>2</sub>-Vasc Score could also have contributed in expanding the number of patients on anticoagulant therapy during the study period.<sup><xref ref-type="bibr" rid="B1">1</xref></sup> Furthermore, considering that total stroke deaths decreased significantly, the epidemiological pattern is comparable to the net benefit of DOACs that has been found in multiple trials.<sup><xref ref-type="bibr" rid="B4">4</xref></sup> The possibility that other factors, such as public health policies, greater cardiovascular risk factor control and improvements in socioeconomic conditions, may have influenced the annual number of deaths cannot be entirely excluded. However, a reduction in hemorrhagic stroke-related deaths would be expected solely from these interventions. Until 2017, a persistent decline in ischemic deaths was still observed, whereas hemorrhagic events continued to increase.<sup><xref ref-type="bibr" rid="B12">12</xref></sup></p>
        <p>Although search scores may provide an estimate of prescription patterns, they are not a direct reflection of regional drug utilization or sales. Internet access in 2014 was available in approximately 50% of all households in Brazil and the illiteracy rate in individuals over 65 years of age was still high (26.4%).<sup><xref ref-type="bibr" rid="B15">15</xref></sup> As such, these patterns must be interpreted considering all of the potential biases, especially because the specific algorithms that were employed by Google Trends were not disclosed. Nevertheless, as Internet access expands throughout the World and new policies are developed to reduce illiteracy rates, search trends will become increasingly more correlated to daily behavioral patterns.</p>
      </sec>
      <sec sec-type="conclusions">
        <title>Conclusion</title>
        <p>The progressive worldwide populational growth has demanded the development of new mechanisms to monitor epidemiological changes in both treatment tendencies and disease patterns. In this context, the Internet has become a valuable tool for gathering information to aid in daily decision making, particularly in health care, where the critical appraisal of the collected data is also of upmost importance. Over the last 10 years, the increasing clinical experience with DOACs in patients with AF has been accompanied by a significant global rise in the popularity of these drugs in Internet search engines. This phenomenon also appears to be occurring in middle-income countries, such as Brazil. However, the association between web-based tendencies and clinical outcomes is still an area that needs further investigation. There is a possibility that the effectiveness of large-scale health care policies and interventions, such as vaccination campaigns, may be monitored by online search data, especially in regions where most of the population have access to the internet. Specific areas in medicine where this strategy may be of value are yet to be determined and should be explored in future studies.</p>
      </sec>
    </body>
    <back>
      <ack>
        <title>Acknowledgements</title>
        <p>This study was supported by the Federal University of Rio de Janeiro and the Edson Saad Heart Institute.</p>
      </ack>
      <fn-group>
        <fn fn-type="other">
          <p>Study Association</p>
          <p>This study is not associated with any thesis or dissertation work.</p>
        </fn>
        <fn fn-type="other">
          <p>Ethics approval and consent to participate</p>
          <p>This article does not contain any studies with human participants or animals performed by any of the authors.</p>
        </fn>
      </fn-group>
      <fn-group>
        <fn fn-type="supported-by">
          <p>Sources of Funding</p>
          <p>There were no external funding sources for this study.</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
